Search results
Results from the WOW.Com Content Network
Dennis Joseph Slamon (born August 6, 1948), [1] [2] is an American oncologist and chief of the division of Hematology-Oncology at UCLA.He is best known for his work identifying the HER2/neu oncogene that is amplified in 25–33% of breast cancer patients and the resulting treatment trastuzumab.
ERBB is abbreviated from erythroblastic oncogene B, a gene originally isolated from the avian genome. The human protein is also frequently referred to as HER2 (human epidermal growth factor receptor 2) or CD340 (cluster of differentiation 340). [5] [6] [7] HER2 is a member of the human epidermal growth factor receptor (HER/EGFR/ERBB) family ...
Teleplay writer Vivienne Radkoff had the story for about seven years before it was completed. It is an adaptation of Robert Bazell's book HER-2: The Making of Herceptin, a Revolutionary Treatment for Breast Cancer. The film was the first mainstream feature film to be scored as a solo project by composer Halli Cauthery.
America Unearthed was an American entertainment television series and the first original series to air on the A&E Networks channel H2. [2] The show premiered on December 21, 2012, and was produced by Committee Films of Minneapolis, Minnesota. [ 3 ]
The following is a list of episodes from World Channel series America ReFramed, a production of American Documentary, Inc.. Since 2012, America ReFramed has broadcast over 120 films by independent filmmakers. [1] [2]
Karyn Hascal, The Healing Place’s president and CEO, said she would never allow Suboxone in her treatment program because her 12-step curriculum is “a drug-free model. There’s kind of a conflict between drug-free and Suboxone.” For policymakers, denying addicts the best scientifically proven treatment carries no political cost.
Of the first 50 programs, only 19 were original WGBH productions, and the first Nova episode, "The Making of a Natural History Film", was originally an episode of Horizon that premiered in 1972. [4] The practice continues to this day.
Efficacy was evaluated in HERIZON-BTC-01 (NCT04466891), an open-label multicenter, single-arm trial in 62 participants with unresectable or metastatic HER2-positive (IHC3+) biliary tract cancer. [2] Participants were required to have received at least one prior gemcitabine -containing regimen in the advanced disease setting.